{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:00:05Z","timestamp":1791932405269,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.03.015","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T20:10:59Z","timestamp":1679083859000},"page":"2696-2706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial"],"prefix":"10.1016","volume":"41","author":[{"given":"Gregory J.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benigno","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying Sue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7824-0106","authenticated-orcid":false,"given":"Ian","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Trahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Kalams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Hannaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pensiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9018-9796","authenticated-orcid":false,"given":"Theresa","family":"Latham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-6319","authenticated-orcid":false,"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-1283","authenticated-orcid":false,"given":"Maurine D.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-1530","authenticated-orcid":false,"given":"Marnie","family":"Elizaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.015_b0005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/M21-0111","article-title":"SARS-CoV-2 Vaccines: Much Accomplished","volume":"174","author":"Connors","year":"2021","journal-title":"Much Learn Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.03.015_b0010","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.015_b0015","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.015_b0020","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0025","unstructured":"FDA. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health:FDA; 2019."},{"issue":"ofv082","key":"10.1016\/j.vaccine.2023.03.015_b0030","article-title":"First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum","volume":"2","author":"Fuchs","year":"2015","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.015_b0035","doi-asserted-by":"crossref","first-page":"e0202753","DOI":"10.1371\/journal.pone.0202753","article-title":"Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial","volume":"13","author":"Elizaga","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.03.015_b0040","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00263-17","article-title":"DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8(+) T-Cell Responses by Interleukin-12 Plasmid DNA","volume":"24","author":"Li","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-1-4614-9632-8_29","article-title":"DNA electroporation of multi-agent vaccines conferring protection against select agent challenge: TriGrid delivery system","volume":"1121","author":"Keane-Myers","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0050","doi-asserted-by":"crossref","first-page":"e19252","DOI":"10.1371\/journal.pone.0019252","article-title":"In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers","volume":"6","author":"Vasan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.03.015_b0055","doi-asserted-by":"crossref","first-page":"e0233151","DOI":"10.1371\/journal.pone.0233151","article-title":"Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial","volume":"15","author":"Mpendo","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.03.015_b0060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/aid.2019.0239","article-title":"A Systematic Approach to HIV-1 Vaccine Immunogen Selection","volume":"36","author":"Bontempo","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.03.015_b0065","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00586-005-1044-x","article-title":"Pain assessment","volume":"15","author":"Haefeli","year":"2006","journal-title":"Eur Spine J"},{"key":"10.1016\/j.vaccine.2023.03.015_b0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.vaccine.2023.03.015_b0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.926","article-title":"Force NHVTNV-IST. Vaccine-induced HIV seropositivity\/reactivity in noninfected HIV vaccine recipients","volume":"304","author":"Cooper","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.03.015_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination","volume":"323","author":"Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2023.03.015_b0085","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/cyto.a.22218","article-title":"OMIP-014: validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining","volume":"81","author":"De Rosa","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.vaccine.2023.03.015_b0090","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1016\/j.vaccine.2021.06.066","article-title":"AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period","volume":"39","author":"Huang","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.015_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01843-17","article-title":"HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees","volume":"92","author":"Yates","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0100","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2023.03.015_b0110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cyto.a.21084","article-title":"High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses","volume":"79","author":"Pollara","year":"2011","journal-title":"Cytometry A"},{"key":"10.1016\/j.vaccine.2023.03.015_b0115","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1128\/JVI.73.11.8966-8974.1999","article-title":"A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor","volume":"73","author":"Trkola","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0120","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.3389\/fimmu.2019.02741","article-title":"Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells","volume":"10","author":"Fisher","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0125","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1128\/JVI.00156-14","article-title":"HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities","volume":"88","author":"Pollara","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.03.015_b0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1198\/sbr.2009.0008","article-title":"Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development","volume":"1","author":"Huang","year":"2009","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.vaccine.2023.03.015_b0135","article-title":"Robust antibody and cellular responses induced by DNA-only vaccination for HIV. JCI","volume":"5","author":"De Rosa","year":"2020","journal-title":"Insight"},{"key":"10.1016\/j.vaccine.2023.03.015_b0140","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.03.015_b0145","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1016\/j.vaccine.2020.08.001","article-title":"Characterization of rVSVDeltaG-ZEBOV-GP glycoproteins using automated capillary western blotting","volume":"38","author":"Minsker","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.015_b0150","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Yahalom-Ronen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.03.015_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/v11020159","article-title":"Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector","volume":"11","author":"Bresk","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.03.015_b0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12981-017-0179-2","article-title":"Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses","volume":"14","author":"Racine","year":"2017","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.vaccine.2023.03.015_b0165","article-title":"Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI","volume":"5","author":"Fischinger","year":"2020","journal-title":"Insight"},{"key":"10.1016\/j.vaccine.2023.03.015_b0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41541-021-00305-8","article-title":"Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans","volume":"6","author":"Seaton","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.03.015_b0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.qai.0000248356.48501.ff","article-title":"Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial","volume":"44","author":"Russell","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2023.03.015_b0180","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(20)30229-0","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study","volume":"7","author":"Baden","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2023.03.015_b0185","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and bivalent subtype C gp120\/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1\/2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2023.03.015_b0190","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults","volume":"384","author":"Gray","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.015_b0195","unstructured":"Gray GE, Mngadi K, Lavreys L, et al. Phase IIb Efficacy Trial of Mosaic Hiv-1 Vaccine Regimen in African Women: Imbokodo. In: Conference of Retroviruses and Opportunistic Infections. (Virtual)."},{"key":"10.1016\/j.vaccine.2023.03.015_b0200","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:56Z","timestamp":1759404296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":40,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23002621"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}